In the Americas, EGFR amplification was associated with a markedly increased risk of mortality (HR = 1.53, 95% CI: 1.28–1.84) (Figure 5b and Figure S3b), indicating that EGFR amplification can serve as a stronger prognostic marker for GBM patients in this region. The gene discussed is EGFR; the disease is glioblastoma.